Baptist Health Lexington
- Type
- Teaching hospital
- Where
- Lexington, KY
- Medicare CCN
- 180103
- Received
- $2,449,614 in 626 records, 2024 ($87,858 general, $2,361,755 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 56 | $87,858 |
| 2024 | Research payment | 570 | $2,361,755 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 570 | $2,361,755 |
| Space rental or facility fees (teaching hospital only) | 17 | $22,087 |
| Education | 5 | $21,250 |
| Long term medical supply or device loan | 20 | $20,696 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 10 | $11,075 |
| Grant | 3 | $7,750 |
| Charitable Contribution | 1 | $5,000 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $16,752 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab ver | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Intuitive Surgical, Inc. | $4,250 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $3,234 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2024 |
| 2024-12-31 | Masimo Corporation | $642 | Long term medical supply or device loan | Cash or cash equivalent | NOMOLINE Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $265 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $265 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $265 | Long term medical supply or device loan | Cash or cash equivalent | rainbow Acoustic Monitoring Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $199 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $199 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $199 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $199 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $199 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $199 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $177 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $177 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $177 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $177 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $177 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-31 | Masimo Corporation | $177 | Long term medical supply or device loan | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2024 | |
| 2024-12-23 | ABBVIE INC. | $9,854 | Research payment | Cash or cash equivalent | ELAHERE Drug, ONCOLOGY | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, F | 2024 |
| 2024-12-23 | Biosense Webster, Inc. | $4,415 | Research payment | Cash or cash equivalent | THERMOCOOL SMARTTOUCH Device, Cardiology | Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH(TM) SF Catheter with the TRUPULSE(TM) Generator for tre | 2024 |
| 2024-12-20 | Biosense Webster, Inc. | $6,080 | Research payment | Cash or cash equivalent | THERMOCOOL SMARTTOUCH Device, Cardiology | Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH(TM) SF Catheter with the TRUPULSE(TM) Generator for tre | 2024 |
| 2024-12-18 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-12-17 | HOLOGIC INC | $57,951 | Research payment | Cash or cash equivalent | P20-08 | 2024 | |
| 2024-12-17 | Gilead Sciences, Inc. | $4,212 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-12-17 | Medtronic, Inc. | $664 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-12-17 | Abbott Laboratories | $550 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, STRUCTURAL HEART | Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antago | 2024 |
| 2024-12-17 | Boston Scientific Corporation | $350 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | LUX-DX TRENDS | 2024 |
| 2024-12-13 | TOLMAR, INC. | $1,116 | Research payment | Cash or cash equivalent | Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Rece | 2024 | |
| 2024-12-12 | Genentech, Inc. | $8,658 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Ocrelizumab PPMS High Dose Study | 2024 |
| 2024-12-12 | Daiichi Sankyo Inc. | $325 | Research payment | Cash or cash equivalent | DS8201-A-U305 | 2024 | |
| 2024-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FRUZAQLA Drug, ONCOLOGY | 2024 | |
| 2024-12-06 | Stryker Corporation | $729 | Research payment | Cash or cash equivalent | AEQUALIS FLEX REVIVE Device, TRAUMA & EXTREMITIES | AEQUALIS FLEX REVIVE STUDY (REVIVE); CIP 20F-W-REVIVE-RM | 2024 |
| 2024-12-05 | ABBVIE INC. | $19,400 | Research payment | Cash or cash equivalent | Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budi | 2024 | |
| 2024-12-05 | Daiichi Sankyo Inc. | $4,178 | Research payment | Cash or cash equivalent | DS1062-A-U301 | 2024 | |
| 2024-12-04 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-12-03 | GENZYME CORPORATION | $2,000 | Research payment | Cash or cash equivalent | LEMTRADA Biological, Neurology | A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profi | 2024 |
| 2024-12-03 | GENZYME CORPORATION | $750 | Research payment | Cash or cash equivalent | LEMTRADA Biological, Neurology | A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profi | 2024 |
| 2024-11-29 | Stryker Corporation | $7,441 | Research payment | Cash or cash equivalent | THE CITADEL EMBOLIZATION DEVICE FEASIBILITY STUDY | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $3,775 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $3,775 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $3,775 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $3,775 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $3,775 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,992 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,355 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,228 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,228 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,228 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,228 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,009 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,009 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,009 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,009 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $2,009 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,840 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,840 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,840 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,840 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,672 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,672 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,672 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,672 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,672 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,672 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,672 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,672 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,672 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,387 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,387 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,387 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,387 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,387 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $1,352 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $186 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $150 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $150 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $150 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $150 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $150 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $150 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-27 | TOLMAR, INC. | $150 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-11-26 | Stryker Corporation | $3,570 | Research payment | Cash or cash equivalent | AEQUALIS PERFORM REVERSED Device, TRAUMA & EXTREMITIES | PERFORM HUMERAL SYSTEM STUDY (PHS) | 2024 |
| 2024-11-26 | Impulse Dynamics (USA) Inc. | $1,200 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-11-22 | TOLMAR, INC. | $3,215 | Research payment | Cash or cash equivalent | Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Rece | 2024 | |
| 2024-11-22 | TOLMAR, INC. | $2,631 | Research payment | Cash or cash equivalent | Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Rece | 2024 | |
| 2024-11-22 | TOLMAR, INC. | $1,116 | Research payment | Cash or cash equivalent | Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Rece | 2024 | |
| 2024-11-19 | Gilead Sciences, Inc. | $2,038 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-11-19 | Genentech, Inc. | $620 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | 2024 |
| 2024-11-14 | Stryker Corporation | $5,500 | Research payment | Cash or cash equivalent | SURPASS EVOLVE Device, FLOW DIVERTER | EVOLVE | 2024 |
| 2024-11-14 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | Device, General - Structural Heart_IC | 2024 | |
| 2024-11-14 | Impulse Dynamics (USA) Inc. | $300 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-11-13 | BIOTRONIK INC. | $1,750 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2024 |
| 2024-11-13 | Tandem Diabetes Care, Inc. | $900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-11-11 | Biosense Webster, Inc. | $16,060 | Research payment | Cash or cash equivalent | THERMOCOOL SMARTTOUCH Device, Cardiology | Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH(TM) SF Catheter with the TRUPULSE(TM) Generator for tre | 2024 |
| 2024-11-08 | Genentech, Inc. | $9,849 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Ocrelizumab PPMS High Dose Study | 2024 |
| 2024-11-06 | Genentech, Inc. | $28,519 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Ocrelizumab PPMS High Dose Study | 2024 |
| 2024-11-06 | Sumitomo Pharma America, Inc. | $11,444 | Research payment | Cash or cash equivalent | ORGOVYX Drug, HORMONE THERAPY | A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS BEING TREATED WITH ORGOVYX | 2024 |
| 2024-11-06 | Tandem Diabetes Care, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-11-06 | Abbott Laboratories | $212 | Research payment | Cash or cash equivalent | AMPLATZER TALISMAN Device, STRUCTURAL HEART | AMPLATZER PFO Occluder Post Approval Study (PFO PAS) | 2024 |
| 2024-11-01 | Genentech USA, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Phesgo Biological, BioOncology | 2024 | |
| 2024-11-01 | Genentech USA, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Phesgo Biological, BioOncology | 2024 | |
| 2024-11-01 | Stryker Corporation | $729 | Research payment | Cash or cash equivalent | AEQUALIS FLEX REVIVE Device, TRAUMA & EXTREMITIES | AEQUALIS FLEX REVIVE STUDY (REVIVE); CIP 20F-W-REVIVE-RM | 2024 |
| 2024-10-31 | AstraZeneca Pharmaceuticals LP | $18,709 | Research payment | Cash or cash equivalent | A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with | 2024 | |
| 2024-10-30 | Abbott Laboratories | $5,824 | Research payment | Cash or cash equivalent | AMPLATZER AMULET Device, STRUCTURAL HEART | CATALYST IDE Study | 2024 |
| 2024-10-30 | Tandem Diabetes Care, Inc. | $1,775 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-10-30 | ZOLL Respicardia, Inc. | $300 | Research payment | Cash or cash equivalent | remede System Device, Respiratory | ZOLL Respicardia, Inc. Registry Study | 2024 |
| 2024-10-28 | Genentech, Inc. | $3,685 | Research payment | Cash or cash equivalent | Tecentriq Biological, BioOncology | Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 | 2024 |
| 2024-10-21 | Abbott Laboratories | $8,535 | Research payment | Cash or cash equivalent | GALLANT Device, CARDIAC RHYTHM MANAGEMENT | SyncAV Post Market Trial | 2024 |
| 2024-10-21 | Abbott Laboratories | $291 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMPLATZER Device, Structural Heart | 2024 | |
| 2024-10-21 | Abbott Laboratories | $171 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMPLATZER Device, Structural Heart | 2024 | |
| 2024-10-18 | Stryker Corporation | $2,690 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIATHLON TRITANIUM CONE AUGMENTS OUTCOMES STUDY | 2024 |
| 2024-10-18 | Stryker Corporation | $1,020 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIATHLON TRITANIUM CONE AUGMENTS OUTCOMES STUDY | 2024 |
| 2024-10-15 | GENZYME CORPORATION | $15,938 | Research payment | Cash or cash equivalent | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 | |
| 2024-10-15 | GENZYME CORPORATION | $4,850 | Research payment | Cash or cash equivalent | Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalima | 2024 | |
| 2024-10-15 | Contego Medical, Inc | $2,745 | Research payment | Cash or cash equivalent | Neuroguard IEP Device, Cardiovascular | Performance II | 2024 |
| 2024-10-15 | Genentech, Inc. | $1,439 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Ocrelizumab PPMS High Dose Study | 2024 |
| 2024-10-14 | Biosense Webster, Inc. | $27,900 | Research payment | Cash or cash equivalent | THERMOCOOL SMARTTOUCH Device, Cardiology | Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH(TM) SF Catheter with the TRUPULSE(TM) Generator for tre | 2024 |
| 2024-10-08 | Boston Scientific Corporation | $13,850 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | AVANT GUARD | 2024 |
| 2024-10-08 | Boston Scientific Corporation | $511 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | ASAP- TOO | 2024 |
| 2024-10-04 | E.R. Squibb & Sons, L.L.C. | $8,521 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination Wi | 2024 |
| 2024-10-04 | Stryker Corporation | $2,940 | Research payment | Cash or cash equivalent | TORNIER PERFORM ANATOMIC AUGMENTED GLENOID Device, BONE SUBSTITUTE | PERFORM HUMERAL SYSTEM STUDY (PHS) | 2024 |
| 2024-10-04 | Stryker Corporation | $1,974 | Research payment | Cash or cash equivalent | AEQUALIS PERFORM REVERSED Device, TRAUMA & EXTREMITIES | TORNIER PERFORM STEMLESS REVERSE IDE STUDY (19B-W-PERFORM-R) | 2024 |
| 2024-10-03 | Roche Products Limited | $295 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2024 |
| 2024-10-03 | Roche Products Limited | $295 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2024 |
| 2024-10-03 | Roche Products Limited | $295 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2024 |
| 2024-10-03 | Roche Products Limited | $295 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2024 |
| 2024-10-03 | Roche Products Limited | $295 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2024 |
| 2024-10-03 | Roche Products Limited | $295 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2024 |
| 2024-10-03 | Roche Products Limited | $295 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2024 |
| 2024-10-03 | Roche Products Limited | $295 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2024 |
| 2024-10-03 | Roche Products Limited | $295 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2024 |
| 2024-10-03 | Roche Products Limited | $295 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment | 2024 |
| 2024-09-30 | BeiGene USA, Inc. | $25,650 | Research payment | Cash or cash equivalent | BRUKINSA Drug, Oncology | A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalido | 2024 |
| 2024-09-30 | Biosense Webster, Inc. | $10,250 | Research payment | Cash or cash equivalent | THERMOCOOL SMARTTOUCH Device, Cardiology | Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH(TM) SF Catheter with the TRUPULSE(TM) Generator for tre | 2024 |
| 2024-09-30 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-09-30 | Intuitive Surgical, Inc. | $4,250 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-09-26 | MicroVention, Inc. | $4,800 | Research payment | Cash or cash equivalent | WEB ANEURYSM EMBOLIZATION SYSTEM Device, NEUROLOGICAL PRODUCT | POST APPROVAL STUDY - EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF THE WEB DEVICE (WEB PAS) | 2024 |
| 2024-09-25 | Medtronic, Inc. | $6,117 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-09-25 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-09-24 | Boston Scientific Corporation | $6,500 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | MODULAR ATP | 2024 |
| 2024-09-24 | Medtronic, Inc. | $4,756 | Research payment | Cash or cash equivalent | REVEAL LINQ Device, Cardiac Diagnostics and Monitoring | ALLEVIATE-HF | 2024 |
| 2024-09-24 | Boston Scientific Corporation | $3,000 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | OPTION | 2024 |
| 2024-09-18 | Merck Sharp & Dohme LLC | $29,429 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab ver | 2024 |
| 2024-09-17 | Gilead Sciences, Inc. | $5,440 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-09-17 | Abbott Laboratories | $240 | Research payment | In-kind items and services | AMPLATZER AMULET Device, STRUCTURAL HEART | CATALYST IDE Study | 2024 |
| 2024-09-16 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Ocrevus Biological, Immunology | Ocrelizumab PPMS High Dose Study | 2024 |
| 2024-09-13 | TOLMAR, INC. | $2,631 | Research payment | Cash or cash equivalent | Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Rece | 2024 | |
| 2024-09-13 | TOLMAR, INC. | $1,116 | Research payment | Cash or cash equivalent | Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Rece | 2024 | |
| 2024-09-13 | TOLMAR, INC. | $1,116 | Research payment | Cash or cash equivalent | Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Rece | 2024 | |
| 2024-09-09 | Biosense Webster, Inc. | $16,640 | Research payment | Cash or cash equivalent | THERMOCOOL SMARTTOUCH Device, Cardiology | Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH(TM) SF Catheter with the TRUPULSE(TM) Generator for tre | 2024 |
| 2024-09-05 | E.R. Squibb & Sons, L.L.C. | $1,125 | Research payment | Cash or cash equivalent | Connect MM The Multiple Myeloma Disease Registry | 2024 | |
| 2024-09-05 | Impulse Dynamics (USA) Inc. | $425 | Research payment | Cash or cash equivalent | OPTIMIZER Device, Cardiovascular Device | Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy | 2024 |
| 2024-09-05 | Medtronic, Inc. | $350 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-09-05 | Medtronic, Inc. | $30 | Research payment | Cash or cash equivalent | AURORA EV-ICD MRI SURESCAN Device, Implantable Cardioverter Defibrillators (ICDs) | PSR-CVG | 2024 |
| 2024-09-03 | Edwards Lifesciences Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-09-03 | Edwards Lifesciences Corporation | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-08-28 | Stryker Corporation | $1,000 | Research payment | Cash or cash equivalent | TRITANIUM Device, HIPS | TRIATHLON TRITANIUM CONE AUGMENTS OUTCOMES STUDY | 2024 |
| 2024-08-28 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 Insulin Pump with Control-IQ Device, Endocrinology | 2024 | |
| 2024-08-27 | Boston Scientific Corporation | $1,322 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_PI | HI-PEITHO | 2024 |
| 2024-08-27 | Boston Scientific Corporation | $1,010 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | ADVANTAGE AF | 2024 |
| 2024-08-26 | Medical Device Business Services, Inc. | $2,000 | Research payment | Cash or cash equivalent | WaveCrest Vs. Watchman Transseptal LAA Closure to Reduce AF Mediated Stroke 2 | 2024 | |
| 2024-08-22 | Daiichi Sankyo Inc. | $9,150 | Research payment | Cash or cash equivalent | DS8201-A-U305 | 2024 | |
| 2024-08-21 | Gilead Sciences, Inc. | $5,508 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-08-20 | Gilead Sciences, Inc. | $2,430 | Research payment | Cash or cash equivalent | A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly | 2024 | |
| 2024-08-15 | Incyte Corporation | $101,444 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasi | 2024 | |
| 2024-08-15 | Biosense Webster, Inc. | $30,280 | Research payment | Cash or cash equivalent | THERMOCOOL SMARTTOUCH Device, Cardiology | Safety and Effectiveness Evaluation of the THERMOCOOL SMARTTOUCH(TM) SF Catheter with the TRUPULSE(TM) Generator for tre | 2024 |
| 2024-08-13 | Boston Scientific Corporation | $3,000 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, WATCHMAN_IC | ASAP- TOO | 2024 |
| 2024-08-13 | Boston Scientific Corporation | $2,615 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | ADVANTAGE AF | 2024 |
| 2024-08-13 | Abbott Laboratories | $2,400 | Research payment | Cash or cash equivalent | GALLANT Device, CARDIAC RHYTHM MANAGEMENT | SyncAV Post Market Trial | 2024 |
| 2024-08-09 | TOLMAR, INC. | $2,355 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-08-09 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-08-09 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-08-09 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-08-09 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-08-09 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-08-09 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 | |
| 2024-08-09 | TOLMAR, INC. | $250 | Research payment | Cash or cash equivalent | A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Inje | 2024 |
The latest 200 records of 626.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Lexington-Fayette, KY, county Fayette County, KY, state Kentucky; placed by its city name.
| Measure | Place (city or town) Lexington-Fayette, KY | County Fayette County, KY | State Kentucky |
|---|---|---|---|
| Population B01003 | 323,725 | 323,725 | 4,534,824 |
| Population, 2020 census P1 | 322,570 | 322,570 | 4,505,836 |
| Median age B01002 | 35.3 | 35.3 | 39.1 |
| Under 18 B01001 | 21.0% | 21.0% | 22.6% |
| 65 and over B01001 | 14.7% | 14.7% | 17.3% |
| Households B11001 | 139,715 | 139,715 | 1,814,469 |
| Foreign born B05002 | 11.9% | 11.9% | 4.7% |
| Median household income B19013 | $69,479 | $69,479 | $63,726 |
| Median family income B19113 | $98,855 | $98,855 | $81,505 |
| Per capita income B19301 | $43,790 | $43,790 | $35,821 |
| Poverty rate B17001 | 14.9% | 14.9% | 16.1% |
| Unemployment rate B23025 | 4.9% | 4.9% | 4.9% |
| Civilian labor force B23025 | 180,472 | 180,472 | 2,152,038 |
| Mean commute (minutes) B08013 | 20.9 | 20.9 | 24.0 |
| Bachelor's degree or higher B15003 | 48.3% | 48.3% | 27.6% |
| Housing units B25001 | 148,959 | 148,959 | 2,023,116 |
| Owner-occupied B25003 | 53.8% | 53.8% | 68.3% |
| Renters B25003 | 46.2% | 46.2% | 31.7% |
| Median home value B25077 | $293,500 | $293,500 | $205,600 |
| Median gross rent B25064 | $1,164 | $1,164 | $967 |
| White, not Hispanic B03002 | 66.7% | 66.7% | 81.5% |
| Black B03002 | 14.4% | 14.4% | 7.6% |
| Hispanic or Latino B03002 | 9.5% | 9.5% | 5.0% |
| Asian B03002 | 4.3% | 4.3% | 1.6% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Economy now FRED unemployment 4.7% in Sep 2026 (4.5% a year earlier); per capita personal income $60,835 in 2025, up 29% in five years (+3.9% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Lexington-Fayette, KY.
Comments